Cardiac and renal complications of carfilzomib in patients with multiple myeloma-Reference-Cited by-同舟云学术

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Published:2017-02-27 Issue:7 Volume:1 Page:449-454
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Dimopoulos Meletios A.¹^ORCID,Roussou Maria¹,Gavriatopoulou Maria¹,Psimenou Erasmia¹,Ziogas Dimitrios¹,Eleutherakis-Papaiakovou Evangelos¹,Fotiou Despina¹,Migkou Magdalini¹,Kanellias Nikolaos¹,Panagiotidis Ioannis¹,Ntalianis Argyrios¹,Papadopoulou Elektra¹,Stamatelopoulos Kimon¹,Manios Efstathios¹,Pamboukas Constantinos¹,Kontogiannis Sofoklis¹,Terpos Evangelos¹,Kastritis Efstathios¹^ORCID

Affiliation:

1. Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Abstract

Key Points Carfilzomib is associated with reversible cardiotoxicity in 12% of consecutive myeloma patients. Transient renal toxicity is common, but carfilzomib may improve renal function in myeloma-related renal impairment.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/7/449/878156/advances003269.pdf

Reference32 articles.

1. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome;Demo;Cancer Res,2007

2. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events;Arastu-Kapur;Clin Cancer Res,2011

3. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma;Lendvai;Blood,2014

4. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma;Siegel;Blood,2012

5. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies;Siegel;Haematologica,2013

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lactoferrin ameliorates carfilzomib-induced renal and pulmonary deficits: Insights to the inflammasome NLRP3/NF-κB and PI3K/Akt/GSK-3β/MAPK axes;Life Sciences;2023-12

2. Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan;Cancer Medicine;2023-09-26

3. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL);American Journal of Hematology;2023-06-19

4. Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network;Frontiers in Oncology;2023-04-25

5. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy;Current Problems in Cardiology;2023-03